The key points of the latest World Health Organization (WHO) classification of noninvasive urothelial tumors are the following: the description of the categories has been expanded to improve their recognition; a tumor with particularly good prognosis (papillary urothelial neoplasm of low malignant potential) no longer carries the label of ‘cancer’; it avoids the use of ambiguous grading such as grade 1/2 or 2/3 (as done in the 1973 WHO classification); the group of noninvasive high-grade carcinoma is large enough to virtually contain all those tumors having biological properties similar to those seen in invasive urothelial carcinoma, and a similarly high level of genetic instability. This scheme is meant to replace the 1973 WHO classification, but the use of both the 1973 and the latest WHO classifications is recommended until the latter is sufficiently validated.
Montironi R, Lopez-Beltran A, Mazzucchelli R, Bostwick DG. Classification and grading of the noninvasive urothelial neoplasms: Recent advances and controversies. J Clin Pathol56:91-952003
2.
Montironi R, Scarpelli M, Mazzucchelli R, Hamilton PW, Thompson D, Ranger-Moore J, Bostwick DG, Bartels PH. Subvisual changes in chromatin organization state are detected by karyometry in the histologically normal urothelium in patients with synchronous papillary carcinoma. Hum Pathol314:893-9012003
3.
Sauter G, Algaba F, Amin MB, Busch C, Cheville J, Gasser T, Grignon D, Hofstaedter F, Lopez-Beltran A, Epstein JI. Noninvasive urothelial neoplasias: WHO classification of noninvasive papillary urothelial tumors. In World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Eble JN, Epstein JI, Sesterhenn I (eds): Lyon, IARCC Press, p. 110, 2004
4.
Lopez-Beltran A, Luque RJ, Moreno A, Bollito E, Carmona E, Montironi R. The pagetoid variant of bladder urothelial carcinoma in situ: A clinicopathological study of 11 cases. Virchows Arch441:148-1532002
5.
Lopez-Beltran A, Cheng L, Andersson L, Brausi M, de Matteis A, Montironi R, Sesterhenn I, van der Kwast KT, Mazerolles C. Preneoplastic nonpapillary lesions and conditions of the urinary bladder: An update based on the Ancona International Consultation. Virchows Arch440:3-112002
6.
Hartmann A, Moser K, Kriegmair M, Hofstetter A. Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol154:721-7271999
7.
Muto S, Horie S, Takahashi S, Tomita K, Kitamura T. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res60:4021-40252000
8.
Epstein JI, Amin MB, Reuter VR. Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol22:1435-14481998
9.
Harnden P, Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol78:870-8751996
10.
Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F, Knuechel R. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res62:809-8182002
11.
Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol23:443-4471999
12.
McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB. Morphologic expressions of urothelial carcinoma in situ: A detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol25:356-3622001
13.
Helpap B, Kollermann J. Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: A contribution to the new WHO classification of the urothelial tumors of the urinary bladder. Hum Pathol31:745-7502000
14.
Bostwick DG, Ramnani D, Cheng L. Diagnosis and grading of bladder cancer and associated lesions. Urol Clin North Am26:493-5071999
15.
Cordon-Cardo C, Cote RJ, Sauter G. Genetic and molecular markers of urothelial premalignancy and malignancy. Scand J Urol Nephrol34(Suppl):82-93, 2000
16.
Simon R, Jones PA, Sidransky D, Cordon-Cardo C, Cairns P, Amin MB, Gasser T, Knowles MA. Genetics and predictive factors of noninvasive urothelial neoplasias. WHO classification of noninvasive papillary urothelial tumors. In World Health Organization Classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Eble JN, Epstein JI, Sesterhenn I (eds): Lyon, IARCC Press, pp. 120-123, 2004
17.
Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol159:394-3981998
18.
McKenney JK, Amin MB, Young RH. Urothelial (transitional cell) papilloma of the urinary bladder: A clinicopathologic study of 26 cases. Mod Pathol16:623-6292003
19.
van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol198:245-2512002
20.
Sauter G. Inverted papilloma. WHO classification of noninvasive papillary urothelial tumors. In World Health Organization Classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Edited by Eble JN, Epstein JI, Sesterhenn I (eds): Lyon, IARCC Press, p. 114, 2004
21.
Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: Relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol165:1124-11282001
22.
Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: The relationship between findings at first follow-up cystoscopy and subsequent recurrence and progression. J Urol167:1634-16372002
23.
Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer86:2102-21081999
24.
Cheng L, MacLennan GT, Zhang S, Wang M, Pan CX, Koch MO. Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer101:183-1882004
25.
Fujii Y, Kawakami S, Koga F, Nemoto T, Kihara K. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int92:559-5622003
26.
Desai S, Lim SD, Jimenez RE, Chun T, Keane TE, McKenney JK, Zavala-Pompa A, Cohen C, Young RH, Amin MB. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pTI papillary urothclial neoplasia. Mod Pathol13:1315-13232000
27.
Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/International Society of Urologic Pathology. Mod Pathol14:267-2722001
28.
Alvarez Kindelan J, Lopez Beltran A, Anglada Curado F, Moreno Arcas P, Carazo Carazo JL, Regueiro Lopez JC, Leva Vallejo M, Prieto Castro R, Requena Tapia MJ. Clinicopathologic differences between bladder neoplasm with low malignant potential and low-grade carcinoma. Actas Urol Esp25:645-6502001
29.
Samaratunga H, Makarov DV, Epstein JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology60:315-3192002
30.
Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Pauwels RP, Newling DW, ten Kate F. Histological grading of papillary urothelial carcinoma of the bladder: Prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol55:900-9052002
31.
Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Navone R. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. Am J Surg Pathol25:1528-15332001
32.
Schmitz-Drager BJ, van Roeyen CR, Grimm MO, Gerharz CD, Decken K, Schulz WA, Bultel H, Makri D, Ebert T, Ackermann R. P53 accumulation in precursor lesions and early stages of bladder cancer. World J Urol12:79-831994
33.
Lopez Beltran A, Bassi P, Pavone-Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol45:257-2662004
34.
Bostwick DG, Mikuz G. Urothelial papillary (exophytic) neoplasms. Virchows Arch441:109-1162002
35.
Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch441:105-1082002
36.
Richter J, Jiang F, Gorog JP, Sartorius G, Egenter C, Gasser TC, Moch H, Mihatsch MJ, Sauter G. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res57:2860-28641997
37.
Richter J, Wagner U, Schraml P, Maurer R, Alund G, Knonagel H, Moch H, Mihatsch MJ, Gasser TC, Sauter G. Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer. Cancer Res59:5687-56911999
